Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome

Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia Syndrome -Multi-center, Open-label, historical Control Comparative Study-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223816

Enrollment

Registered

2018-02-20

Start date

2018-04-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Fever with Thrombocytopenia Syndrome (SFTS)

Interventions

investigational material(s) Generic name etc : Favipiravir(T-705) INN of investigational material : Favipiravir Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age:20 years old to less than 85 years old 2.Sex: No restriction 3.Outpatient/hospitalization: Hospitalization 4.Patients who are strongly suspected of SFTS

Exclusion criteria

Exclusion criteria: 1.Patients who have shown a trend toward improvement of symptoms. 2.Patients who are using ribavirin or has used ribavirin for this episode of infection 3.Others

Design outcomes

Primary

Measure	Time frame
safety efficacy Efficacy and Safety	—

Secondary

Measure	Time frame
pharmacokinetics pharmacokinetics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026